DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Adalimumab
Drug: Methotrexate

First Posted Date: 2010-08-19

Last Posted Date: 2014-03-18

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 309

Registration Number: NCT01185288

Locations: 🇺🇸
Site Reference ID/Investigator# 43049, Danbury, Connecticut, United States
🇵🇷
Site Reference ID/Investigator# 60850, San Juan, Puerto Rico
🇵🇷
Site Reference ID/Investigator# 60851, Vega Baja, Puerto Rico

and more 46 locations

Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Early Rheumatoid Arthritis

Interventions: Biological: adalimumab
Drug: methotrexate

First Posted Date: 2010-08-19

Last Posted Date: 2013-11-15

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 395

Registration Number: NCT01185301

Locations: 🇦🇹
Site Reference ID/Investigator# 44928, Graz, Austria
🇵🇱
Site Reference ID/Investigator# 44984, Warsaw, Poland
🇵🇷
Site Reference ID/Investigator# 39692, Vega Baja, Puerto Rico

and more 65 locations

Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life

Completed

Conditions: Psoriasis

First Posted Date: 2010-07-27

Last Posted Date: 2016-07-13

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 191

Registration Number: NCT01169987

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Phase 3

Completed

Conditions: Enthesitis Related Arthritis (ERA)

Interventions: Biological: adalimumab
Biological: placebo for adalimumab

First Posted Date: 2010-07-21

Last Posted Date: 2021-07-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 46

Registration Number: NCT01166282

The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Device: Adalimumab delivered in Physiolis autoinjector
Device: Adalimumab delivered in current autoinjector
Device: Adalimumab delivered in current syringe
Device: Adalimumab delivered in Physiolis syringe

First Posted Date: 2010-07-16

Last Posted Date: 2018-07-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 85

Registration Number: NCT01163617

Locations: 🇺🇸
Site Reference ID/Investigator# 27144, Victorville, California, United States
🇺🇸
Site Reference ID/Investigator# 27153, Tampa, Florida, United States
🇺🇸
Site Reference ID/Investigator# 27143, Duncansville, Pennsylvania, United States

and more 7 locations

Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-07-15

Last Posted Date: 2015-06-10

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 552

Registration Number: NCT01163318

Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-07-15

Last Posted Date: 2018-07-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 220

Registration Number: NCT01163292

Locations: 🇯🇵
Site Reference ID/Investigator# 54522, Sasebo, Japan
🇯🇵
Site Reference ID/Investigator# 54659, Yotsukaido, Japan
🇯🇵
Site Reference ID/Investigator# 54683, Chiba, Japan

and more 72 locations

A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: adalimumab
Drug: Methotrexate

First Posted Date: 2010-07-14

Last Posted Date: 2016-11-01

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 77

Registration Number: NCT01162421

A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine

Completed

Conditions: HIV Infection

First Posted Date: 2010-07-09

Last Posted Date: 2013-01-24

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 346

Registration Number: NCT01159743

Locations: 🇪🇸
Site Reference ID/Investigator# 39591, Madrid, Spain
🇪🇸
Site Reference ID/Investigator# 39601, Barcelona, Spain
🇪🇸
Site Reference ID/Investigator# 39609, Logrono, Spain

and more 23 locations

Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

Terminated

Conditions: Moderate to Severe Psoriasis

First Posted Date: 2010-07-05

Last Posted Date: 2014-08-25

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 30

Registration Number: NCT01156532

Locations: 🇵🇪
Site Reference ID/Investigator# 56700, Lima, Peru
🇵🇪
Site Reference ID/Investigator# 35783, Lima, Peru
🇵🇪
Site Reference ID/Investigator# 43147, Trujillo, Peru

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy